Skip to Main Content
Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is fairly modest, as usual. We plan to hang with our shortest person, catch up on our reading, and take in another installment in our ‘Let’s-see-them-before-they-die‘ concert series. And what about you? Now that spring is here, you can spend some time outdoors. You can tidy up around the castle and prepare for a garage sale. Or you can simply plan the rest of your life. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon. …

Valeant Pharmaceuticals chief executive Joseph Papa received compensation last year valued at $62.7 million, according to The Wall Street Journal. He took over as the beleaguered drug maker suffered from accounting problems, high debt levels, and various government probes into business practices, including its relationship with a specialty pharmacy. Papa has been trying to sell assets to reduce debt.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Ah, your concert choice. I have been quoting them professionally for years and years. When teams are trying to find certain ‘key items’ or asking about them – my advice is often “Please don’t bother trying to find them, they’re not there.”

Comments are closed.